Allied Market Research

2024

Factor V Leiden Thrombophilia Treatment Market

Factor V Leiden Thrombophilia Treatment Market Size, Share, Competitive Landscape and Trend Analysis Report by Type (Deep Venous Thrombosis (DVT), Pulmonary Embolism (PE)), by Diagnosis (APC (Activated Protein C) Resistance Assay, Targeted Mutation Analysis) and by Treatment (Anticoagulants, Surgery, Hospitals, Ambulatory Surgical Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Factor V Leiden thrombophilia is a genetic disease that increases the likelihood of developing a blood clot at some point in life. Despite this, it is expected that a clot will not form in 95% of Factor V Leiden patients.  When a clot does form, it usually occurs in the legs (deep venous thrombosis or DVT) or the lungs (pulmonary embolism or PE). The name Factor V Leiden refers to a specific gene mutation in the F5 gene, which is involved in the creation of blood clots following an injury. The Factor V Leiden gene mutation can be inherited in one or two copies. This disorder is sometimes misdiagnosed as Factor V deficiency, a genetic bleeding problem that can result in severe bleeding after surgery or trauma. Factor V Leiden thrombophilia may increase the risk of heart attacks, strokes, and pregnancy problems.

COVID-19 Impact Analysis:

Pharmaceutical and biotech companies together with governments globally are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges.

Currently, about 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn, is expected to have a significant impact on the global Factor V Leiden thrombophilia treatment market.

Top Impacting Factors:

  • The increase in geriatric population and the rise in cases of injury, obesity, smoking, surgery, and pregnancy are the primary factors driving market expansion.
  • The rise in the global healthcare expenditure, a surge in diabetic population, the increase in cancer patients, and the increase in the prevalence of cardiovascular disease are factors driving the market growth.
  • The increase in the number of mutations in the F5 gene is expected to drive the Factor V Leiden thrombophilia treatment market during the forecast years.
  • Additionally, the increase in use of oral contraceptives, hormone replacement treatment, and the growth in occurrences of the antiphospholipid syndrome are also expected to boost the market over the forecast period.
  • Furthermore, the introduction of new medications, the increase in R&D activities, and the increase in investment by major companies for Factor V Leiden thrombophilia treatment are boosting the market globally. 
  • However, the lack of awareness in patients regarding Factor V Leiden thrombophilia and lack of skilled health workforce are hampering the growth of the Factor V Leiden thrombophilia market. 

Market Trends:

New Product Launches to Flourish Factor V Leiden Thrombophilia Market

In October 2019, Johnson & Johnson’s Xarelto was approved by the FDA to help prevent blood clots in acutely ill patients without a high risk of bleeding during and after hospitalization. 

In December 2020, Glenmark Pharmaceuticals received a tentative approval by the United States Food and Drug Administration (USFDA) for Dabigatran Etexilate capsules in the strengths of 75 mg, 110 mg, and 150 mg. The approved product is a generic version of Boehringer Ingelheim Pharmaceuticals' Pradaxa capsules.
 

Key Benefits of Report:

  • This study presents the analytical depiction of the Factor V Leiden thrombophilia treatment along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Factor V Leiden thrombophilia treatment market share.
  • The current market is quantitatively analyzed to highlight the Factor V Leiden thrombophilia treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed Factor V Leiden thrombophilia treatment market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in Factor V Leiden Thrombophilia Treatment Market Report:

  • Who are the leading market players active in Factor V Leiden thrombophilia treatment market?
  • What current trends will influence the Factor V Leiden thrombophilia treatment market in the next few years?
  • What are the driving factors, restraints, and opportunities in the Factor V Leiden thrombophilia treatment market?
  • What future projections would help in taking further strategic steps?
  • What is Factor V Leiden thrombophilia treatment?
  • What is Factor V Leiden thrombophilia treatment market prediction in the future?
  • Who are the leading global players in the Factor V Leiden thrombophilia treatment market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the Factor V Leiden thrombophilia treatment market report?

Factor V Leiden Thrombophilia Treatment Market Report Highlights

Aspects Details
Factor V Leiden Thrombophilia Treatment Market By Type
By Type
  • Deep Venous Thrombosis (DVT)
  • Pulmonary Embolism (PE)
Factor V Leiden Thrombophilia Treatment Market By Diagnosis
By Diagnosis
  • APC (Activated Protein C) Resistance Assay
  • Targeted Mutation Analysis
Factor V Leiden Thrombophilia Treatment Market By Treatment
By Treatment
  • Anticoagulants
  • Surgery
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Factor V Leiden Thrombophilia Treatment Market By Region
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players
Key Market Players

C. H. Boehringer Sohn, CoaguSense, Bristol-Myers Squibb, Bayer Group, Portola Pharmaceuticals, Pfizer, Johnson & Johnson, Alere, Siemens, Roche, Daiichi Sankyo, Abbott

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Factor V Leiden Thrombophilia Treatment Market

Global Opportunity Analysis and Industry Forecast, 2023-2032